2+ entry enables physiological stress responses but in excess promotes injury and death. However, tissue-specific in vivo systems for testing the role of mitochondrial Ca 2+ are lacking. We developed a mouse model with myocardial delimited transgenic expression of a dominant negative (DN) form of the mitochondrial Ca 2+ uniporter (MCU). DN-MCU mice lack MCU-mediated mitochondrial Ca 2+ entry in myocardium, but, surprisingly, isolated perfused hearts exhibited higher O 2 consumption rates (OCR) and impaired pacing induced mechanical performance compared with wild-type (WT) littermate controls. In contrast, OCR in DN-MCU-permeabilized myocardial fibers or isolated mitochondria in low Ca 2+ were not increased compared with WT, suggesting that DN-MCU expression increased OCR by enhanced energetic demands related to extramitochondrial Ca 2+ homeostasis. Consistent with this, we found that DN-MCU ventricular cardiomyocytes exhibited elevated cytoplasmic [Ca 2+ ] that was partially reversed by ATP dialysis, suggesting that metabolic defects arising from loss of MCU function impaired physiological intracellular Ca 2+ homeostasis. Mitochondrial Ca 2+ overload is thought to dissipate the inner mitochondrial membrane potential (ΔΨm) and enhance formation of reactive oxygen species (ROS) as a consequence of ischemia-reperfusion injury. Our data show that DN-MCU hearts had preserved ΔΨm and reduced ROS during ischemia reperfusion but were not protected from myocardial death compared with WT. Taken together, our findings show that chronic myocardial MCU inhibition leads to previously unanticipated compensatory changes that affect cytoplasmic Ca 2+ homeostasis, reprogram transcription, increase OCR, reduce performance, and prevent anticipated therapeutic responses to ischemia-reperfusion injury.
Myocardial mitochondrial Ca
2+ entry enables physiological stress responses but in excess promotes injury and death. However, tissue-specific in vivo systems for testing the role of mitochondrial Ca 2+ are lacking. We developed a mouse model with myocardial delimited transgenic expression of a dominant negative (DN) form of the mitochondrial Ca 2+ uniporter (MCU). DN-MCU mice lack MCU-mediated mitochondrial Ca 2+ entry in myocardium, but, surprisingly, isolated perfused hearts exhibited higher O 2 consumption rates (OCR) and impaired pacing induced mechanical performance compared with wild-type (WT) littermate controls. In contrast, OCR in DN-MCU-permeabilized myocardial fibers or isolated mitochondria in low Ca 2+ were not increased compared with WT, suggesting that DN-MCU expression increased OCR by enhanced energetic demands related to extramitochondrial Ca 2+ homeostasis. Consistent with this, we found that DN-MCU ventricular cardiomyocytes exhibited elevated cytoplasmic [Ca 2+ ] that was partially reversed by ATP dialysis, suggesting that metabolic defects arising from loss of MCU function impaired physiological intracellular Ca 2+ homeostasis. Mitochondrial Ca 2+ overload is thought to dissipate the inner mitochondrial membrane potential (ΔΨm) and enhance formation of reactive oxygen species (ROS) as a consequence of ischemia-reperfusion injury. Our data show that DN-MCU hearts had preserved ΔΨm and reduced ROS during ischemia reperfusion but were not protected from myocardial death compared with WT. Taken together, our findings show that chronic myocardial MCU inhibition leads to previously unanticipated compensatory changes that affect cytoplasmic Ca 2+ homeostasis, reprogram transcription, increase OCR, reduce performance, and prevent anticipated therapeutic responses to ischemia-reperfusion injury.
myocardium | mitochondrial calcium uniporter | ischemia-reperfusion injury E ntry of Ca 2+ into the mitochondrial matrix is a central event for Ca 2+ homeostasis in cardiomyocytes (1) as well as for coordinating fundamental and diverse responses to physiological (2) and pathological stress (3) . The paradigm for Ca 2+ as a physiological second messenger that enhances oxidative phosphorylation to enable fight-or-flight responses but in excess contributes to disease and dysfunction is well established in myocardium (4) . The molecular identity of the mitochondrial Ca 2+ uniporter (MCU) was recently discovered, enabling development of new genetic models to understand the role of MCU in vivo. MCU is an ion channel protein that acts as the primary pathway for Ca 2+ entry into the mitochondrial matrix (5, 6) . Recent findings in global Mcu −/− mice (7) suggest that the MCU pathway is dispensable for regulating cellular energy production, except under extreme physiological stress, and for activation of pathways leading to cell death; however, the effect of selective myocardial MCU inhibition is unknown. We developed a new transgenic mouse model with myocardial delimited dominant negative (DN)-MCU protein overexpression to test the role of MCU-mediated Ca 2+ entry for myocardial physiology and pathological stress.
We tested whether loss of MCU-mediated Ca 2+ entry substantially alters myocardial energetics. Surprisingly, we found that DN-MCU hearts had a higher oxygen consumption rate (OCR) due, at least in part, to secondary actions on cytoplasmic Ca 2+ homeostasis. We also found that chronic MCU inhibition failed to protect against myocardial ischemia-reperfusion injury despite reducing generation of reactive oxygen species (ROS). We queried mRNA expression in adult hearts and identified diverse changes in multiple gene pathways induced by DN-MCU
Significance
Mitochondrial Ca 2+ is a fundamental signal that allows for adaptation to physiological stress but a liability during ischemia-reperfusion injury in heart. On one hand, mitochondrial Ca 2+ entry coordinates energy supply and demand in myocardium by increasing the activity of matrix dehydrogenases to augment ATP production by oxidative phosphorylation. On the other hand, inhibiting mitochondrial Ca 2+ overload is promulgated as a therapeutic approach to preserve myocardial tissue following ischemia-reperfusion injury. We developed a new mouse model of myocardial-targeted transgenic dominant-negative mitochondrial Ca 2+ uniporter (MCU) expression to test consequences of chronic loss of MCU-mediated Ca 2+ entry in heart. Here we show that MCU inhibition has unanticipated consequences on extramitochondrial pathways affecting oxygen utilization, cytoplasmic Ca 2+ homeostasis, physiologic responses to stress, and pathologic responses to ischemia-reperfusion injury. (5, 6) . The highly conserved aspartic acid-isoluecinemethionine-glutamic acid motif contains two negatively charged amino acids in the pore-forming linker-loop sequence. DN-MCU with D261Q/E264Q mutations inhibited mitochondrial Ca 2+ uptake in HeLa cells (6) . Based on this information, we developed a myocardial-selective in vivo model of MCU inhibition by transgenic expression of DN-MCU under control of the α-myosin heavy chain (αMHC) promoter (8) (Fig. 1A) . DN-MCU mice were interbred into a CD1 background, based on evidence that CD1 background is permissive for loss of MCU current (9) . DN-MCU mice were born in Mendelian ratios and survived into adulthood. We used a primer set to detect MCU and DN-MCU transcripts and found that the transcript level of Mcu was 60-fold higher in transgenic samples (Fig. 1B) . The Myc-tagged DN-MCU protein was resident only in cardiac mitochondria from DN-MCU transgenic mice (Fig. 1C ) and was detectable with an MCU antibody that showed markedly increased expression in DN-MCU compared with WT heart lysates ( Fig. S1 ).
Increased mitochondrial Ca 2+ can enhance oxidative phosphorylation (10) . Based on the known relationship between mitochondrial Ca 2+ and oxidative phosphorylation, we initially hypothesized that DN-MCU hearts lacking Ca 2+ entry through MCU would have reduced O 2 consumption rates (OCR) compared with WT. Contrary to our expectations, unloaded Langendorff-perfused and ventricular paced DN-MCU hearts consumed more O 2 at 400 (P < 0.05), 600 (P < 0.01), and 750 beats/min (bpm) (P < 0.01) compared with WT (Fig. 1D) . OCR was increased in WT between 400 and 600 bpm (P < 0.01) but not between 600 and 750 bpm. OCR was increased in DN-MCU between 400 and 600 bpm (P < 0.0001) as well as between 600 and 750 bpm (P < 0.05). No differences in cardiac morphology or baseline heart rate ( Fig. 1E and Fig. S2 ) or in the heart weight: body weight ratios (Fig. 1F) were observed. We measured left ventricular (LV) ejection fraction in conscious, unsedated mice and found no difference between groups (Fig. 1G) . No differences were detected between groups in the mitochondrial injury score (3) ( Fig. 1 H and I) , total mitochondrial protein content normalized to heart weight ratios (Fig. 1J ), or mitochondrial-tonuclear DNA content (Fig. 1K) . Additionally, cyclooxygenase 4 (COXIV) protein levels were not different between groups (Fig.  S3 ). These findings suggest that the increase in OCR in DN-MCU hearts was not related to alterations in myocardial or mitochondrial mass or structure but that DN-MCU hearts were less efficient than WT, based on higher OCR.
DN-MCU Expression Decreases Inotropic and Lusitropic Responses to
Stress. In vivo LV pressure measurements showed that DN-MCU mice had increased baseline +dP/dt MAX (the maximal LV pressure change rate during systole) and similar −dP/dt MAX compared with WT. DN-MCU mice showed reduced ±dP/dt MAX responses to isoproterenol (10 μg/kg) compared with WT ( Fig.  S4 A-F) . Based on the defect in myocardial performance in DN-MCU mice in vivo, we repeated the Langendorff-perfused heart studies under conditions suitable for measuring LV pressure. We found that DN-MCU and WT hearts had equal LV-developed pressure (LVDP) at 400 bpm, but DN-MCU hearts had significantly reduced LVDP at 600 and 750 bpm compared with WT (P < 0.01) (Fig. 2 A-G) . DN-MCU hearts had reduced LVDP between 400 and 750 bpm (P < 0.01) and 600 and 750 bpm (P < 0.05). +dP/dt MAX and -dP/dt MAX were not different at 400 bpm, but DN-MCU hearts had diminished ±dP/dt MAX responses at 600 bpm (P < 0.01) and 750 bpm (P < 0.01) ( Fig. 2 G and H) . The +dP/dt MAX was reduced in DN-MCU hearts between 400 and 750 bpm (P < 0.01) and 600 and 750 bpm (P < 0.05) and had significantly diminished -dP/dt MAX between 400 and 750 bpm (P < 0.05) (Fig. 2I ). Under these conditions DN-MCU hearts had significantly higher OCR at 400 and 600 bpm (P < 0.05) (Fig. 2J ). Within groups, OCR at 400 and 750 bpm was significantly different (P < 0.01) in WT, but not in DN-MCU, suggesting that DN-MCU hearts contracting against an afterload have a smaller pacing-induced OCR range than unloaded hearts.
DN-MCU Expression Alters Mitochondrial and Cytoplasmic Ca
2+ Dynamics.
We next tested whether DN-MCU expression in ventricular myocytes prevented rapid mitochondrial Ca 2+ entry. We used freshly isolated adult ventricular myocytes with permeabilized cell membranes and incubated them with Ca 2+ green-5N (CaGr5N), a membrane-impermeable Ca 2+ sensitive fluorescent dye (3). We confirmed that DN-MCU ventricular myocytes and isolated mitochondria had complete or nearly complete loss of mitochondrial Ca 2+ uptake (Fig. 3A and Fig. S5A ), similar to phenotypes observed in cells treated with the MCU antagonist Ru360 (11), lacking MCU expression (7) or expressing DN-MCU (12 ] mt in isolated mitochondria loaded with Fura-4FF. We found that DN-MCU mitochondria had no observable step-wise increase in Fura-4FF signal in response to repetitive Ca 2+ boluses (Fig. S5B) . Furthermore, Ca 2+ uptake in mitochondria isolated from DN-MCU hearts was unaffected by the MCU antagonist Ru360 (Fig. S5B) , confirming that DN-MCU expression ablated the Ru360-sensitive Ca 2+ influx. Taken together, these data show that DN-MCU myocardial mitochondria lack the MCU-mediated, rapid Ca 2+ uptake pathway. Mitochondrial Ca 2+ stimulates pyruvate dehydrogenase phosphatase to dephosphorylate pyruvate dehydrogenase (PDH), increasing its enzymatic activity (13) . We measured PDH phosphorylation in DN-MCU and WT hearts and found that PDH was significantly (P < 0.001) more phosphorylated ( Fig. 3 B and C) and exhibited lower enzyme activity (Fig. 3D) (Fig. S6A) , and aspartate was the only significantly increased metabolite in DN-MCU compared with WT hearts (Fig. S6 B and C) . These data indicate that the lack of MCU-mediated Ca 2+ uptake in DN-MCU mitochondria is sufficient to impair activity of the Ca 2+ -sensitive enzyme PDH, but without widespread changes in myocardial glucose metabolism detectable by NMR.
We next asked whether loss of mitochondrial Ca 2+ uptake would increase cytosolic [Ca 2+ ] in DN-MCU cells, potentially imposing an energy demand on the sarcoplasmic reticulum/ endoplasmic reticulum Ca 2+ -ATPase (SERCA2a). We found significantly higher diastolic and systolic cytoplasmic [Ca 2+ ] in DN-MCU cells (Fig. 3 E-G ) compared with WT, suggesting that chronic MCU inhibition triggers a demand for increased SERCA activity. These findings show that chronic loss of MCU-mediated mitochondrial Ca 2+ uptake in myocardium increased OCR, possibly by enhancing the metabolic cost of cytoplasmic Ca 2+ homeostasis during excitation-contraction coupling.
We recently reported that cardiac pacemaker cells isolated from DN-MCU mice have impaired ATP production and defective cytosolic [Ca 2+ ] homeostasis that was corrected by ATP dialysis (12) . Based on these findings, we asked if ATP deficiency contributed to pacing-induced increases in cytoplasmic [Ca 2+ ] in DN-MCU ventricular myocytes. Fortifying intracellular ATP (5 mM added to the pipette solution) significantly decreased (Wet) ] in WT and DN-MCU hearts. All error bars represent SEM. Sample size (n) indicated for each group in parentheses. *P < 0.05, **P < 0.01, Student's t test. #P < 0.05, ##P < 0.01, and ###P < 0.001 comparing 750 to 400 bpm; $P < 0.05 comparing 750 to 600 bpm, Tukey's post hoc multiple comparison test. ] measurements made with Fura-2-loaded cells stimulated by field stimulation. All error bars represent SEM. *P < 0.05, ***P < 0.001, Student's t test. Sample size (n) indicated for each group in parentheses. cytosolic diastolic [Ca 2+ ] only in DN-MCU ventricular myocytes (Fig. S7 A and B) . In contrast, added ATP equally and slightly decreased systolic cytosolic [Ca 2+ ] in WT and DN-MCU, but did not reach statistical significance (Fig. S7C ). Taken together with findings in DN-MCU pacemaker cells (12), we interpreted these data to suggest that physiologic cytoplasmic [Ca 2+ ] homeostasis requires MCU-mediated ATP production.
Multiple ionic conductances may contribute to differences in cytoplasmic [Ca 2+ ] homeostasis between DN-MCU and WT ventricular myocytes. Therefore, we measured voltage-gated L-type Ca 2+ current (I Ca ), Na + /Ca 2+ exchanger current (I NCX ), and sarcoplasmic reticulum Ca 2+ content (Fig. S8) . We found no difference in I Ca (Fig. S8A) , but I NCX density was increased (Fig. S8B) in DN-MCU cells, suggesting that DN-MCU cells partially rely on NCX to compensate for loss of MCU function. Interestingly, DN-MCU myocytes had reduced SR Ca 2+ content at baseline (P < 0.01) and after isoproterenol treatment (P < 0.0001) compared with WT (Fig. S8C) . We interpreted these data to suggest that MCU-mediated ATP production contributes to SR Ca 2+ loading in ventricular myocytes and that MCU inhibition is accompanied by increases in I NCX .
No Effect of DN-MCU on OCR in Isolated Mitochondria. Mitochondria are an important source of O 2
•-in cardiomyocytes (14) and may induce mitochondrial uncoupling to increase oxygen consumption. Therefore, we used electron paramagnetic resonance (EPR) spin trapping with the cyclic nitrone 5,5-dimethyl-1-pyrroline-Noxide (DMPO) (15) to measure O 2
•-levels from isolated mitochondria. We found a trend (P = 0.07) toward less DMPO-OH signal in DN-MCU mitochondria (Fig. 4 A and B) , suggesting reduced O 2
•-production. Importantly, when antimycin A, a complex III inhibitor and agent known to increase oneelectron reductions of O 2 to form O 2
•-, was included in the reaction mixture the signals from WT and DN-MCU mitochondria increased to similar peak values (Fig. 4B) , indicating that DN-MCU and WT mitochondria have a similar capacity to produce O 2
•-. Addition of superoxide dismutase (SOD) completely quenched the DMPO-OH signal in both DN-MCU and WT mitochondria, indicating that DMPO-OH was reporting on O 2
•-levels with high fidelity. These EPR data demonstrated that loss of MCU-mediated Ca 2+ entry may modestly reduce O 2
•-production in isolated mitochondria. Excessive mitochondrial Ca 2+ entry promotes opening of the mitochondrial permeability transition pore, loss of ΔΨm (16), and release of mitochondrial reactive oxygen species (ROS) (17) , which are consequences of ischemia-reperfusion injury that lead to myocardial death (18) . We adapted our ischemia-reperfusion model to simultaneously measure ΔΨm and ROS in Langendorff-perfused hearts using confocal microscopy. The DN-MCU hearts maintained ΔΨm at baseline values during ischemic stress, whereas WT hearts showed a 19 ± 6% decrease in ΔΨm during ischemia compared with baseline (Fig. S9A) , although the difference in ΔΨm between genotypes was not significantly different (P = 0.12). In the reperfusion interval, WT hearts showed increased ROS compared with DN-MCU hearts (Fig. S9B) . Toward the end of the reperfusion interval the DN-MCU hearts had significantly reduced ROS compared with baseline (P < 0.05), whereas WT hearts did not show a decline in ROS relative to baseline (Fig. S9B) . Additionally, two-way ANOVA revealed that changes in ROS during ischemia reperfusion were significantly different between DN-MCU and WT hearts (P < 0.05). We considered the possibility that reduced ROS in DN-MCU mitochondria could be related to increased reductive enzyme activity. To test this concept, we measured glutathione peroxidase, catalase, Cu/ZnSOD, and MnSOD in freshly isolated whole hearts and found decreased activity of MnSOD and total SOD activity (Fig. S9 C-G) in DN-MCU compared with WT, suggesting that the reduced ROS signal in DN-MCU hearts during ischemia reperfusion was not due to increased antioxidant enzymes. Based on an extensive body of work (16, 19, 20) , we initially hypothesized that lower levels of ROS would result in myocardial protection. However, despite reduction in ROS, the DN-MCU hearts were not protected from cell death following ischemia-reperfusion injury (Fig. S9 H and I) .
Given the increased OCR in DN-MCU hearts, we next asked whether intrinsic properties of DN-MCU mitochondria contribute to high O 2 consumption. First, we studied isolated permeabilized myocardial fibers (21) (bath [Ca 2+ ] = 156 nM) to assess OCR. We found that, in contrast to myocardium with intact cell membranes, DN-MCU fibers consumed significantly less O 2 than WT controls under state 3 conditions (P < 0.05), but had similar OCR relative to WT under state 2 and 4 conditions (Fig. 4C) . ATP concentrations (Fig. 4D) were significantly lower (P < 0.05) in DN-MCU compared with WT samples, suggesting blunted ATP production, higher ATP hydrolysis, or both. The ratio of ATP content:O 2 consumption was not significantly different between DN-MCU and WT fibers (Fig. 4E) . These findings suggest that DN-MCU mitochondria have reduced oxidative capacity compared with WT controls and are not intrinsically uncoupled, at least in the setting of membrane permeabilization and low extramitochondrial Ca . At baseline, we found that isolated DN-MCU mitochondria had similar OCR to WT (Fig. 4F) . DN-MCU and WT mitochondria responded similarly to ADP, oligomycin, FCCP, and antimycin A (Fig. 4G) . Thus, the reduction in mitochondrial respiration in permeabilized DN-MCU fibers and isolated mitochondria in low [Ca 2+ ] compared with isolated hearts suggests that extramitochondrial [Ca 2+ ] contributes to the increased OCR in intact DN-MCU hearts.
Broad Transcriptional Reprogramming in DN-MCU Hearts. Our findings showed that inhibition of MCU has important consequences for cytoplasmic Ca 2+ homeostasis and physiological and pathological stress responses in heart. As a first step toward identifying potential transcriptional foundations for these effects, we profiled transcriptional changes induced by inhibition of MCU by performing microarray analysis to measure mRNA expression levels. We detected 636 genes with more than twofold expression change (false discovery rate < 0.05) in adult DN-MCU mice, relative to WT littermates (Fig. 5A and Table S1 , GSE62049). Functional gene annotation clustering revealed that these genes are significantly enriched for a variety of biological processes, including acetylation, redox biochemistry, and endoplasmic nuclear signaling (Fig. 5B) . We used qRT-PCR to measure mRNA targets from selected functional gene annotation terms and validated these targets with working primer sets (Fig. 5C ). These data support a concept that MCU-mediated mitochondrial Ca 2+ entry has the potential to regulate transcriptional programs controlling diverse cellular pathways in myocardium. Our ANOVA analysis of mRNA expression levels revealed B-cell lymphoma 2 (Bcl2) to be elevated in DN-MCU samples (P = 0.00036). Therefore, we queried other members of the Bcl2 family and found markedly increased expression of the Bcl2-associated X protein (Bax) transcript (upregulated ninefold, P = 0.006, Student's t test) and significantly (P < 0.01) elevated Bax protein expression in DN-MCU heart lysates (Fig. 5 D and E) . Bax is a Bcl-2 family member implicated in mitochondrial-dependent and -independent cell death pathways (22, 23) and has been shown to impact Ca 2+ homeostasis (23) , suggesting that DN-MCU hearts may have increased susceptibility to Bax-mediated death during ischemia-reperfusion injury.
Discussion
We found that loss of MCU causes unanticipated cellular responses that increase OCR, disrupt cytoplasmic Ca 2+ homeostasis, and trigger transcriptional reprogramming. The ability of mitochondria to buffer cytosolic Ca 2+ is controversial (24) (25) (26) . Our findings show that inhibition of MCU increases cytosolic [Ca 2+ ], potentially consistent with a loss of mitochondrial Ca 2+ -buffering capacity and/or ATP deficiency. We recently found that MCU inhibition limited fight-or-flight heart rate increases by lowering ATP below a critical threshold and that dialysis of 4 mM ATP was sufficient to rescue fight-or-flight responses in cardiac pacemaking cells (12) . Thus, it is possible that elevated [Ca 2+ ] in DN-MCU ventricular myocytes is at least partly due to inadequate ATP for physiological Ca 2+ buffering. We observed an abrogation of OCR differences using low [Ca 2+ ] buffers and when mitochondria were tested in buffers nominally lacking Ca 2+ , suggesting that elevation of cytosolic [Ca 2+ ] in DN-MCU hearts contributed to elevated OCR in situ. An elevated or depressed heart rate could increase or decrease OCR (27) , but we controlled for this by measuring OCR at equal pacing intervals. Our in vivo data showed that DN-MCU mice had similar heart rates to WT at baseline, but an inability to increase heart rate after isoproterenol administration, consistent with recent evidence that MCU is necessary for heart rate increases during physiological stress (12) . Rapid pacing in DN-MCU hearts may increase cytosolic [Ca 2+ ] to a greater extent than in WT hearts due to loss of mitochondrial Ca 2+ buffering and/or inadequate ATP to sustain intracellular Ca 2+ homeostasis. Our NMR glucose metabolite measurements did not reveal major differences in metabolites between DN-MCU and WT hearts. However, we cannot exclude the possibility that 13 C was lost as CO 2 through the tricarboxylic acid (TCA) cycle because we measured labeled metabolites in clamp-frozen hearts and not effluents (28) . The amount of glucose uptake in paced hearts is low (29) and was below the limit of detection in our NMR studies. Thus, it is possible that DN-MCU and WT hearts had differences in glucose uptake that were undetected under these experimental conditions.
By selectively eliminating MCU activity in myocardium, our studies revealed an unanticipated feature of the interdependence of cytosolic [ target to protect against cell death (30) . We only tested for cell death in cardiomyocytes and cannot exclude the possibility that chronic MCU inhibition in different cell types could protect from pathologic stimuli. Our findings suggest that further advances in understanding mitochondrial mechanisms governing cell survival and cellular responses to loss of MCU-mediated mitochondrial Ca 2+ entry are required before developing therapies designed to prevent mitochondrial Ca 2+ overload.
Materials and Methods
A complete description can be found in SI Materials and Methods.
Mice Lacking Functional Myocardial MCU. DN-MCU transgenic mice were recently described (12) and generated by αMHC promoter-driven expression of cDNA encoding the dominant negative form of MCU.
In Vivo and ex Vivo Measurements. Hemodynamic and LV pressure measurements were made in anesthetized mice with a 1-F Millar catheter and in isolated, Langendorff-perfused hearts in the presence and absence of a LV pressure transducer. 
